医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

PAREXEL and CHA Medical Group Partner to Enhance Early Phase Clinical Research in Korea

2018年03月13日 PM10:00
このエントリーをはてなブックマークに追加


 

BOSTON

PAREXEL International Corporation, the world’s leading innovator of biopharmaceutical services, today announced an alliance with CHA Medical Group (CHA) to enhance early phase clinical development in Korea. The collaboration is designed to provide biopharmaceutical companies with comprehensive services that leverage PAREXEL’s global clinical research and regulatory expertise with CHA’s experience conducting early phase studies in Korea.

A growing hub for drug development, Korea is ranked sixth in the world for the number of clinical trials conducted in the country,1 and is an attractive location for early phase trials due to government investment in the industry and access to patients. Additionally, Korea’s regulatory requirements, modeled after the U.S. Food and Drug Administration (FDA), enable sponsors to use the data from early clinical studies conducted in the country for global development.

“Enrollment challenges are a primary cause of delays in Phase I/II studies which involve target patient populations, and many companies struggle with gaining access to patients while conducting trials in a safe and controlled environment,” said Stanford Jhee, PharmD, Corporate Vice President, Early Phase Scientific Affairs at PAREXEL. “With this partnership we are aiming to bring our biopharmaceutical clients interested in conducting trials in Korea not only broad access to patients, but the expertise necessary to conduct the trials from start to finish, generate quality Phase I data needed for global development and gain the market advantage essential to commercial success.”

PAREXEL has 28 offices and 7,150 employees across the Asia Pacific region, and established operations in Korea in 2000. Through the partnership, PAREXEL and CHA have recently completed a Phase I First-in-Human clinical trial at CHA’s flagship facility in Seoul, South Korea.

About PAREXEL International

PAREXEL International Corporation is the world’s leading innovator of biopharmaceutical services. We simplify our clients’ journey of transforming scientific discoveries into new medical treatments for patients with high-quality Phase I-IV clinical research, regulatory, consulting and market access services. PAREXEL develops breakthrough innovations and solutions by leveraging its comprehensive therapeutic, technical and functional expertise, in more than 100 countries around the world. For more information, visit www.PAREXEL.com.

1 Business Korea, “Due to High-quality Medical Services Seoul Ranks First in the World in Number of Clinical Trials per City.”

View source version on businesswire.com: http://www.businesswire.com/news/home/20180313005142/en/

CONTACT

PAREXEL Contacts:
Media:
Dana Robie
Tel.:
+1 781-434-4772
Email: Dana.Robie@PAREXEL.com
or
Kathryn
McMahon Arrigg, PAN Communications
Tel.: +1 617-502-4300
Email:
PAREXEL@pancomm.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • Takeda to Divest TachoSil® to Corza Health for €350 Million
  • 新たな研究:ハンドドライヤーによる手の乾燥はペーパータオルと同じくらい衛生的
  • Body Fit Training PTY LTD Sues to Invalidate F45 Training PTY LTD’s U.S. Patents
  • Singapore and Apple Partner on National Health Initiative Using Apple Watch
  • 最新研究:干手机与用纸巾擦干双手一样卫生